Core Viewpoint - The approval of a new specification for the drug Treprostinil Injection by the National Medical Products Administration of China marks a significant advancement for the company in the treatment of pulmonary arterial hypertension (PAH) [1] Group 1: Product Approval - The new specification (20ml:50mg) for Treprostinil Injection has recently received a drug registration certificate [1] - The previous specification (20ml:20mg) was approved for market launch in March 2023 [1] - Both specifications are included in the medical insurance catalog, allowing for more precise treatment options for clinicians based on patient needs [1] Group 2: Clinical Significance - Treprostinil is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, effectively treating PAH symptoms [1] - Clinical studies have demonstrated the long-term efficacy and safety of Treprostinil, with one-year and four-year survival rates of 88% and 70%, respectively [1] - Treprostinil Injection is a first-line treatment and a foundational drug in targeted combination therapies for PAH [1] Group 3: Market Impact - The approval of Treprostinil Injection alters the market landscape by breaking the previous monopoly of a single product in the domestic market [1] - This development is expected to further reduce the medical burden on PAH patients [1]

Group 1: Product Development and Regulatory Approvals - The company has received a drug registration certificate from the National Medical Products Administration of China for a new specification (20ml:50mg) of its product, Treprostinil injection, used for treating pulmonary arterial hypertension (PAH) [1] - The existing specification (20ml:20mg) was approved for market launch in March 2023, and both specifications are included in the medical insurance catalog, allowing for more precise treatment options for clinicians [1] - The company has reached an equity investment and product cooperation agreement with Shanghai Zhongqiang Pharmaceutical Co., Ltd., which includes acquiring approximately 14.42% equity and exclusive commercialization rights for Treprostinil inhalation formulation in Greater China [2] Group 2: Market Potential and Epidemiology - PAH is a rare cardiovascular disease with an incidence rate of approximately 2.4 per million person-years and a prevalence of about 15 per million, leading to high mortality and disability rates [3] - The global PAH market is projected to reach approximately $8.06 billion in 2024, with a compound annual growth rate (CAGR) of 5.3%, and the Asia-Pacific region expected to grow at a CAGR of 13.3% [3] Group 3: Clinical Efficacy and Treatment Landscape - Treprostinil is a synthetic prostacyclin analog that promotes vasodilation and inhibits platelet aggregation, with clinical studies showing significant long-term efficacy and safety [4] - The one-year and four-year survival rates for patients on Treprostinil monotherapy are 88% and 70%, respectively, indicating a substantial improvement in patient prognosis [4] - The approval of Treprostinil injection has altered the market landscape by reducing the monopoly of single products in the domestic market, potentially lowering the medical burden on PAH patients [4] Group 4: Commitment to Rare Diseases and Innovation - The company is focused on developing treatments for rare diseases, with over 20 products in the pipeline, including those for conditions like N-acetylglutamate synthase deficiency and hyperammonemia [5] - The company aims to address the clinical needs in the rare disease sector, responding to government and societal calls, and is committed to increasing the development of effective treatments for rare diseases [5] - The company emphasizes innovation and advanced technology in product development, aiming to create a global sales network and enhance its international presence [6][7]

Core Viewpoint - The company has made significant progress in the treatment of pulmonary arterial hypertension (PAH) with the approval of a new specification for its drug, which will enhance treatment options for patients [1][4]. Group 1: Product Development and Approval - The company received a drug registration certificate from the National Medical Products Administration for a new specification (20ml: 50mg) of its drug for PAH treatment, complementing the previously approved 20ml: 20mg specification [1]. - The new specifications will allow clinicians to provide more precise treatment plans based on patient needs, marking a major advancement in the rare disease sector of cardiovascular emergency care [1]. - The company has also entered into an equity investment and product cooperation agreement with Shanghai Zhongqiang Pharmaceutical, acquiring approximately 14.42% equity and exclusive commercialization rights for various formulations of its PAH treatment [2]. Group 2: Market Potential and Epidemiology - PAH is a rare cardiovascular disease with an incidence rate of approximately 2.4 per million person-years and a prevalence of about 15 per million, indicating a significant unmet medical need [3]. - The global PAH market is projected to reach approximately $8.06 billion in 2024, with a compound annual growth rate (CAGR) of 5.3%, and the Asia-Pacific region expected to grow at a CAGR of 13.3% [3]. Group 3: Clinical Efficacy and Treatment Landscape - The drug, a synthetic prostacyclin analog, has demonstrated long-term efficacy and safety in clinical studies, with survival rates of 88% and 70% at one and four years, respectively [4]. - The approval of the injection solution has altered the market dynamics, potentially reducing the financial burden on PAH patients [4]. Group 4: Commitment to Rare Diseases - The company is focused on developing treatments for rare diseases, with over 20 products in the pipeline, including those for conditions like N-acetylglutamate synthase deficiency and Cushing's disease [5]. - The company aims to address the significant challenges faced by rare disease patients, where only 5% of such diseases have effective treatments available [5]. Group 5: Innovation and Global Strategy - The company emphasizes innovation and advanced technology in product development, aiming to meet unmet clinical needs and enhance its product pipeline [6][7]. - A strategy of global operational layout and dual-circulation development is being adopted to promote domestic and international growth [6][7].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Grand Pharmaceutical Group Limited 遠大醫藥集團有限公司* ( 於百慕達註冊成立之有限公司 ) (股份代號: 00512) 自願性公告 曲前列尼爾注射液（20ml : 50mg）獲頒發藥品註冊證書 本公告乃遠大醫藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）之 董事會（「董事會」）自願刊發。 董事會欣然公告，本集團用於治療肺動脈高壓（pulmonary arterial hypertension， 「PAH」，WHO 分類 1）的產品曲前列尼爾注射液的新規格（20ml : 50mg），近日獲 得中華人民共和國國家藥品監督管理局（中國藥監局）頒發藥品註冊證書，本產品 20ml:20mg 的規格已於二零二三年三月獲批上市。本產品爲醫保目錄產品，兩種規格 將有助於臨床醫生根據患者的情況提供更加精准的治療方案，這是本集團在心腦血管 急救領域罕見病方向的重大進展。 本集 ...

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Core Insights - The recent clinical study of Yuan Da Pharmaceutical's product, Chen Nuo (Eucalyptus Oil Enteric Capsules), has been recognized by an international journal, marking a significant milestone in its evidence-based medical validation [1][3][10] - The study demonstrated the safety and efficacy of Chen Nuo in treating chronic rhinosinusitis over an 8-week period, reinforcing the company's research capabilities in the respiratory field [3][5][7] Product and Market Position - Chen Nuo is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its mucolytic properties and has been included in China's national medical insurance and essential drug lists since 2017 and 2018 respectively [4][10] - The clinical trial involved over 300 patients across 13 hospitals, comparing the efficacy of Chen Nuo combined with Budesonide nasal spray against Budesonide alone [4][5] Clinical Study Results - Results indicated that the combination therapy group showed a statistically significant improvement in symptom control rates compared to the control group, particularly in nasal congestion and discharge by the 8th week [5][7] - The study also highlighted the advantages of the combination therapy for chronic rhinosinusitis patients with a history of smoking, showing greater improvement in CT Lund-Mackay scores [5][7] Future Market Potential - The research supports the inclusion of Chen Nuo in standardized treatment pathways for chronic rhinosinusitis, potentially benefiting over 100 million patients in China, especially those with smoking histories [7] - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7][8] Product Pipeline and Innovation - Yuan Da Pharmaceutical has developed a comprehensive product portfolio in the respiratory and critical care sectors, including treatments for various respiratory diseases and conditions [11][12] - The company is advancing multiple innovative products, including Ryaltris for allergic rhinitis and STC3141 for sepsis, which are expected to enhance its competitive position in the market [12][16] Strategic Development - The company emphasizes innovation and advanced technology in its R&D strategy, aiming to establish a full-cycle management product cluster for chronic respiratory diseases and critical care [16]

Core Viewpoint - The recent clinical study of Yuan Da Pharmaceutical's Cheno® (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in the product's evidence-based medical validation [1][3]. Product and Clinical Research - Cheno® is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its mucolytic properties and has been included in China's national medical insurance and essential drug lists since 2017 and 2018 respectively [4][5]. - The study involved over 300 chronic rhinosinusitis patients across 13 top-tier hospitals in China, comparing the efficacy and safety of Cheno® combined with Budesonide nasal spray against Budesonide alone [4][5]. Study Results - The results indicated that the combination therapy group showed a statistically significant improvement in major symptom scores and symptom control rates compared to the control group [5]. - Notably, the combination therapy was particularly effective for chronic rhinosinusitis patients with a smoking history, demonstrating superior improvement in CT Lund-Mackay scores [5][6]. - The safety profile of Cheno® was confirmed, with no significant difference in adverse event rates compared to the control group [5][6]. Market Position and Future Potential - The study reinforces Cheno®'s clinical value and supports its inclusion in standardized treatment pathways for chronic rhinosinusitis, potentially benefiting over 100 million patients in China, especially those with a smoking history [6]. - Cheno® is not only indicated for chronic rhinosinusitis but also has applications in various respiratory diseases, indicating a vast market potential [6]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from $11.6 billion to $13.8 billion by 2028 at a CAGR of 4.5% [6]. Product Pipeline and Innovation - Yuan Da Pharmaceutical has developed a comprehensive product portfolio in the respiratory and critical care sectors, including innovative formulations for asthma and allergic rhinitis, with several products recently entering the national medical insurance list [11][12]. - The company is also advancing its pipeline with promising candidates for sepsis and other critical conditions, enhancing its competitive edge in the market [12][13]. - The strategic focus on innovation and global expansion aims to solidify the company's position in the respiratory disease management sector [16].

Core Viewpoint - Recent clinical research on Yuan Da Pharmaceutical's product Qino (Eucalyptol enteric-coated capsules) for chronic rhinosinusitis has been recognized by an international journal, marking a significant milestone in evidence-based medicine for the product [1][3]. Group 1: Clinical Research and Product Validation - The study, led by Professor Wang Dehui from Fudan University, involved over 300 patients across 13 major hospitals in China and demonstrated the safety and efficacy of Qino when used in conjunction with Budesonide nasal spray [4][5]. - Results indicated that the combination therapy significantly improved symptom scores and control rates compared to the control group, particularly in patients with a history of smoking [5][7]. - This research fills a gap in evidence for long-term combination therapy, supporting Qino's inclusion in standardized treatment pathways for chronic rhinosinusitis [7]. Group 2: Market Position and Growth Potential - Qino is a core product in Yuan Da Pharmaceutical's respiratory and critical care segment, recognized for its clinical significance and market leadership in cough and phlegm relief [4][10]. - The global respiratory drug market is projected to reach approximately $99.9 billion by 2024, with the Chinese market expected to grow from about $11.6 billion to $13.8 billion by 2028, at a compound annual growth rate of 4.5% [7]. - Yuan Da Pharmaceutical has a diverse product pipeline addressing various respiratory conditions, including asthma and chronic obstructive pulmonary disease, enhancing its competitive edge in the market [11][12]. Group 3: Future Development and Strategic Focus - The company emphasizes innovation and advanced technology in product development, aiming to create a comprehensive management product cluster for chronic respiratory diseases and critical care [16]. - Yuan Da Pharmaceutical's strategic focus on both domestic and international markets is expected to strengthen its industry position and drive valuation growth [15].

来源：市场资讯 （来源：ETF万亿指数） 美联储降息终于落地了降。 25bp符合预期，点阵图显示年内还要降两次，有点鸽派；但是鲍威尔的表态又"不够鸽派"，so，有点纠 结。 所以，涨跌都有理，有句话说的好，符合预期就是利好兑现，跌。 对了，还有Good Afternoon的梗... 如果鲍威尔说"Good Afternoon"，就是偏鹰派，不降息或者降息没超预期，跌。 如果他说"Hello Everyone"，那就是鸽，要降息，涨！ 华尔街机构也早早的部署好了AI系统，第一时间捕捉到他舌头的微小变化，来决定买卖了... 有点失望的是，鲍威尔这回的开场是"Good Afternoon"。 自这之后，美股先涨后跌，大A似乎也复制了同样的走势，不得不服啊这预判。 那，今天聊聊降息下，大家比较关注的创新药板块，调整后还没有没有机会。 一、创新药，三重压力下暂时回调 港股通创新药ETF（520880）在连续9个交易日调整后，场内却延续高频溢价，买盘资金依然强势，这 辆创新药高速列车是否在等待更多人上车？ 港股通创新药ETF基金经理丰晨成解读，近期调整主要源于三重因素叠加： 1、行业催化空窗期：缺乏大BD（商务拓展）催化 ...

Core Viewpoint - YuanDa Pharmaceutical (00512) is deepening its strategy in urological diagnosis and treatment products, aiming to unlock a market potential worth billions through strategic investments in the urology field [1][3]. Group 1: Strategic Cooperation - The company has signed a cooperation agreement with Shanghai Yingte Weilu Medical Device Co., Ltd. to obtain global exclusive commercialization rights for the VTAS steam ablation product for treating benign prostatic hyperplasia (BPH) [1]. - This strategic cooperation aligns with YuanDa's dual focus on "products" and "technology," creating a new pattern of "channel expansion" and "innovation collaboration" [3]. - The partnership will accelerate market penetration post-product launch and enhance the research collaboration, solidifying YuanDa's global strategic layout in the urology diagnosis and treatment sector [3][12]. Group 2: Market Potential and Technology - BPH is a common urological condition among middle-aged and elderly men, with a prevalence rate of 60% in men over 60 and up to 90% in those aged 70-80, affecting over 100 million men in China [4]. - Traditional treatment methods include medication and invasive surgeries, which have limitations such as impact on sexual function and surgical risks [4][5]. - The steam ablation technology offers a minimally invasive solution, with advantages such as short operation time (under 10 minutes), low recurrence rates, and high safety, making it a promising alternative in the BPH treatment landscape [6][7]. Group 3: Product Features and Innovations - The VTAS steam ablation system is the only BPH steam ablation product in China with a core patent for steam generation and control, enhancing treatment efficacy and safety [6]. - VTAS features advanced energy control precision, stable steam output, and a unique puncture structure design ensuring 100% puncture success [6][7]. - The product is compatible with most bladder scopes and incorporates self-developed algorithms and AI-assisted functions for personalized treatment [7]. Group 4: Broader Product Ecosystem - YuanDa has developed a comprehensive product cluster in the urology field, covering various conditions including urinary tract cancer and prostate cancer, enhancing its market control [8]. - The company holds exclusive commercialization rights for several innovative products, including early detection tools for urinary tract cancer, which have received breakthrough device designation from the FDA [8][9]. - YuanDa's Go Global strategy aims to establish a global pharmaceutical brand, leveraging its full industry chain capabilities in the nuclear medicine and high-end medical device sectors [12].